SCHEMBL1433503

SCHEMBL1433503

CC(C)(NC(=O)c1cc2c(NC(=O)c3ccc(CN4CCOCC4)cc3)nn(C(=O)OCCF)c2s1)c1ccccc1F

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.43
BCR P11274 1/20 0.43
RAB9A P51151 6/20 0.40
HIF1A Q16665 4/20 0.40
EPAS1 Q99814 4/20 0.40
PDE7A Q13946 1/20 0.39
NPC1 O15118 4/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
LMNA P02545 2/20 0.39
TP53 P04637 2/20 0.39
MAPK1 P28482 2/20 0.38
MAPT P10636 1/20 0.38
TSHR P16473 1/20 0.38
STAT3 P40763 1/20 0.38
MAPK14 Q16539 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1434258 0.95 ABL1 (0.43) ABL1BCRRAB9AHIF1AEPAS1
SCHEMBL1433365 0.95 ABL1 (0.43) ABL1BCRRAB9AHIF1AEPAS1
SCHEMBL1433822 0.95 ABL1 (0.43) ABL1BCRRAB9AHIF1AEPAS1
SCHEMBL1433702 0.94 RAB9A (0.44) ABL1BCRRAB9AHIF1AEPAS1
SCHEMBL1434445 0.94 ABL1 (0.42) ABL1BCRRAB9AHIF1AEPAS1
SCHEMBL1435025 0.93 ABL1 (0.41) ABL1BCRRAB9AHIF1AEPAS1
SCHEMBL1434134 0.93 ABL1 (0.43) ABL1BCRRAB9AHIF1AEPAS1
SCHEMBL1433773 0.93 ABL1 (0.45) ABL1BCRRAB9AHIF1AEPAS1
SCHEMBL1891808 0.92 ABL1 (0.41) ABL1BCRRAB9AHIF1AEPAS1
SCHEMBL1434324 0.92 ABL1 (0.41) ABL1BCRRAB9AHIF1AEPAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8809337-B2 Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-08-19 US claimed
US-20130203770-A1 CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-08-08 US claimed
US-20110118278-A1 CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-19 US claimed
US-8809337-B2 Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-08-19 US disclosed
US-20130203770-A1 CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-08-08 US disclosed
US-20110118278-A1 CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-19 US disclosed
EP-2300436-A1 CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS Nerviano Medical Sciences S.r.l. (IT) 2011-03-30 EP disclosed
WO-2009138440-A1 CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203770-A1 CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS DMPK, DCK, MAP3K19 ABL1 556/4885BCR 600/4885RAB9A 1562/4885
US-20110118278-A1 CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS DMPK, DCK, MAP3K19 ABL1 556/4885BCR 600/4885RAB9A 1562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.